Export this Abstract | Print this Abstract | Add to my preferred Abstracts list | My preferred Abstracts list (1) | Back to Search
Development of PEGylated aspartic acid modified liposome as a bone-targeting carrier for the delivery of paclitaxel and treatment of bone metastasis
- In: Poster Presentation
- At: Stockholm (Sweden) (2017)
- Type: Poster
- Poster code: P-B-117-Tuesday
- By: YAMASHITA, Shugo (Kyoto Pharmaceutical University, Biopharmaceutics, Kyoto, Japan)
- Co-author(s): Shugo Yamashita: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Hidemasa Katsumi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Nozomi Hibino: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Yugo Isobe: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Yumiko Yagi: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Yuka Tanaka: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Saki Yamada: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Kosuke Kusamori: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Toshiyasu Sakane: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan
Akira Yamamoto: Biopharmaceutics, Kyoto Pharmaceutical University, Kyoto, Japan - Abstract:
Backgrounds
The number of bone metastasis patients has been rapidly increasing in association with the global population aging. However, most anticancer drugs do not have a high affinity for bone hydroxyapatite under physiological conditions. Therefore, development of bone targeting system is highly required for the treatment of bone metastasis. In .. The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 28 September 2023